EVALUATION OF THE EFFECTIVENESS OF ANTICOAGULANT THERAPY IN PATIENTS WITH CHRONIC GLOMERULONEPHRITIS USING THE EXAMPLE OF TREATMENT HEPARIN AND RIVAROXABAN
DOI:
https://doi.org/10.5281/zenodo.11280934Abstract
Evaluation of the Effectiveness of Anticoagulant Therapy in Patients with Chronic Glomerulonephritis: A Comparative Study of Heparin and Rivaroxaban Treatment
References
Levin A, Stevens PE, Bilous RW, et al. Kidney disease: improving
global outcomes (KDIGO) CKD work group. KDIGO 2012 clinical practice guideline for the evaluation and Management of Chronic Kidney
Jain N, Reilly RF. Clinical pharmacology of oral anticoagulants in
patients with kidney disease. Clin J Am Soc Nephrol. 2019;14(2)278-287.
Lutz J, Jurk K, Schinze H, et al. Direct oral anticoagulants in patients
with chronic kidney disease: patient selection and special considerations.
Int J Nephrol Renovasc Dis. 2017;10:135-143.
Barra ME, Fanikos J, Connors JM, Sylvester KW, Piazza G,
Goldhaber SZ. Evaluation of dose-reduced direct oral anticoagulant
therapy. Am J Med. 2016;129:1198-1204.
Chronic kidney disease and anticoagulation: from vitamin K antagonists and heparins to direct oral anticoagulant agents Savino Sciascia1,2 • Massimo Radin1.Karen Schreiber3,4 • Roberta Fenoglio2 • Simone Baldovino1,2 • Dario Roccatello1,2 Received: 28 June 2017 / Accepted: 11 September 2017 / Published online: 19 September 2017
Benefits and Harms of Oral Anticoagulant Therapy in Chronic Kidney Disease A Systematic Review and Meta-analysis Jeffrey T. Ha, MBBS; Brendon L. Neuen, MBBS(Hons); Lap P. Cheng, MBBS; Min Jun, PhD; Tadashi Toyama, PhD; Martin P. Gallagher, PhD; Meg J. Jardine, PhD; Manish M. Sood, MD; Amit X. Garg, PhD; Suetonia C. Palmer, PhD; Patrick B. Mark, PhD; David C. Wheeler, MD; Vivekanand Jha, MD; Ben Freedman, PhD; David W. Johnson, PhD; Vlado Perkovic, PhD; and Sunil V. Badve, PhD.
Sin CF, Wong KP, Wong HM, Siu CW, Yap DYH. Plasma rivaroxaban level in patients with early stages of chronic kidney diseaserelationships with renal function and clinical events. Front Pharmacol. 2022;13:888660.
